SCHEMBL4760331

SCHEMBL4760331

COc1cc2ncnc(Nc3ccc(CC(=O)NCCCCCCNC(=O)O)cc3)c2cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.63
FLT4 P35916 2/20 0.63
KDR P35968 16/20 0.63
FLT3 P36888 2/20 0.61
EGFR P00533 5/20 0.58
HDAC3 O15379 4/20 0.57
HDAC4 P56524 4/20 0.57
HDAC1 Q13547 4/20 0.57
HDAC7 Q8WUI4 4/20 0.57
HDAC2 Q92769 4/20 0.57
HDAC10 Q969S8 4/20 0.57
HDAC11 Q96DB2 4/20 0.57
HDAC8 Q9BY41 4/20 0.57
HDAC6 Q9UBN7 4/20 0.57
HDAC9 Q9UKV0 4/20 0.57
HDAC5 Q9UQL6 4/20 0.57
RET P07949 2/20 0.56
GAK O14976 1/20 0.56
RIPK2 O43353 1/20 0.56
STK10 O94804 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14081284 0.93 KDR (0.68) PDGFRBFLT4KDRFLT3EGFR
SCHEMBL5556064 0.92 PDGFRB (0.62) PDGFRBFLT4KDRFLT3EGFR
Hydrochloric Acid SCHEMBL4758921 0.91 PDGFRB (0.61) PDGFRBFLT4KDRFLT3EGFR
SCHEMBL14081368 0.84 PDGFRB (0.54) PDGFRBFLT4KDRFLT3EGFR
SCHEMBL14081354 0.84 PDGFRB (0.54) PDGFRBFLT4KDRFLT3EGFR
SCHEMBL4760833 0.84 KDR (0.69) PDGFRBFLT4KDRFLT3EGFR
SCHEMBL23703468 0.76 EGFR (0.77) PDGFRBFLT4KDREGFRHDAC3
SCHEMBL25682990 0.76 KDR (0.78) KDRFLT3EGFRRETGAK
SCHEMBL18158179 0.75 EGFR (0.79) KDRFLT3EGFRRETGAK
SCHEMBL22300265 0.75 EGFR (0.71) KDRFLT3EGFRRETGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7413727-B2 Contrast agents GE HEALTHCARE AS (NO) 2008-08-19 US disclosed
EP-1442751-B1 Diagnostic imaging technique GE HEALTHCARE AS (NO) 2007-06-20 EP disclosed
EP-1442751-A1 Method of imaging Amersham Health AS (NO) 2004-08-04 EP disclosed
EP-0977600-B1 CONTRAST AGENTS TARGETTING RECEPTORS ASSOCIATED WITH ANGIOGENESIS AMERSHAM HEALTH AS (NO) 2004-06-30 EP disclosed
US-20040009122-A1 Contrast agents AMERSHAM HEALTH AS (NO) 2004-01-15 US disclosed
US-6610269-B1 Disease state imaged using a targeted contrast agent of the formula V-L-R, where V is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker, R is a macromolecular or particulate label AMERSHAM HEALTH AS (NO) 2003-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009122-A1 Contrast agents FLT1, FLT4, KDR PDGFRB 181/4885FLT4 2/4885KDR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.